vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.
Dominari Holdings Inc. is the larger business by last-quarter revenue ($30.1M vs $20.6M, roughly 1.5× Pulmonx Corp). Pulmonx Corp runs the higher net margin — -66.3% vs -438.1%, a 371.8% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs -8.7%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs -0.5%).
Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.
DOMH vs LUNG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $20.6M |
| Net Profit | $-131.8M | $-13.7M |
| Gross Margin | — | 77.9% |
| Operating Margin | -8.9% | -40.9% |
| Net Margin | -438.1% | -66.3% |
| Revenue YoY | 220.4% | -8.7% |
| Net Profit YoY | -12426.2% | 5.5% |
| EPS (diluted) | $-6.94 | $-0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $20.6M | ||
| Q4 25 | $30.1M | $22.6M | ||
| Q3 25 | $50.8M | $21.5M | ||
| Q2 25 | $34.1M | $23.9M | ||
| Q1 25 | $8.1M | $22.5M | ||
| Q4 24 | $9.4M | $23.8M | ||
| Q3 24 | $4.0M | $20.4M | ||
| Q2 24 | $6.2M | $20.8M |
| Q1 26 | — | $-13.7M | ||
| Q4 25 | $-131.8M | $-10.4M | ||
| Q3 25 | $125.2M | $-14.0M | ||
| Q2 25 | $16.6M | $-15.2M | ||
| Q1 25 | $-32.5M | $-14.4M | ||
| Q4 24 | $1.1M | $-13.2M | ||
| Q3 24 | $-4.2M | $-14.1M | ||
| Q2 24 | $-6.1M | $-15.3M |
| Q1 26 | — | 77.9% | ||
| Q4 25 | — | 77.6% | ||
| Q3 25 | — | 74.7% | ||
| Q2 25 | — | 72.1% | ||
| Q1 25 | — | 72.5% | ||
| Q4 24 | — | 74.0% | ||
| Q3 24 | — | 73.7% | ||
| Q2 24 | — | 73.7% |
| Q1 26 | — | -40.9% | ||
| Q4 25 | -8.9% | -43.8% | ||
| Q3 25 | -3.1% | -66.9% | ||
| Q2 25 | -57.0% | -62.0% | ||
| Q1 25 | -394.6% | -64.6% | ||
| Q4 24 | 0.4% | -56.5% | ||
| Q3 24 | -79.1% | -69.3% | ||
| Q2 24 | -44.3% | -75.2% |
| Q1 26 | — | -66.3% | ||
| Q4 25 | -438.1% | -46.1% | ||
| Q3 25 | 246.4% | -64.9% | ||
| Q2 25 | 48.7% | -63.6% | ||
| Q1 25 | -400.5% | -64.1% | ||
| Q4 24 | 11.4% | -55.4% | ||
| Q3 24 | -104.2% | -69.4% | ||
| Q2 24 | -99.1% | -73.7% |
| Q1 26 | — | $-0.33 | ||
| Q4 25 | $-6.94 | $-0.25 | ||
| Q3 25 | $7.27 | $-0.34 | ||
| Q2 25 | $1.12 | $-0.38 | ||
| Q1 25 | $-3.02 | $-0.36 | ||
| Q4 24 | $0.21 | $-0.33 | ||
| Q3 24 | $-0.67 | $-0.36 | ||
| Q2 24 | $-1.01 | $-0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $61.6M |
| Total DebtLower is stronger | — | $37.3M |
| Stockholders' EquityBook value | $69.4M | $45.8M |
| Total Assets | $112.9M | $120.0M |
| Debt / EquityLower = less leverage | — | 0.82× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $61.6M | ||
| Q4 25 | $80.5M | $69.8M | ||
| Q3 25 | $176.2M | $76.5M | ||
| Q2 25 | $28.2M | $75.5M | ||
| Q1 25 | $18.9M | $74.6M | ||
| Q4 24 | $8.2M | $70.9M | ||
| Q3 24 | $7.2M | $63.3M | ||
| Q2 24 | $12.1M | $63.5M |
| Q1 26 | — | $37.3M | ||
| Q4 25 | — | $37.1M | ||
| Q3 25 | — | $37.1M | ||
| Q2 25 | — | $37.1M | ||
| Q1 25 | — | $37.2M | ||
| Q4 24 | — | $37.2M | ||
| Q3 24 | — | $37.2M | ||
| Q2 24 | — | $37.2M |
| Q1 26 | — | $45.8M | ||
| Q4 25 | $69.4M | $54.1M | ||
| Q3 25 | $210.2M | $60.0M | ||
| Q2 25 | $88.6M | $69.1M | ||
| Q1 25 | $42.4M | $77.7M | ||
| Q4 24 | $39.9M | $85.8M | ||
| Q3 24 | $38.3M | $93.9M | ||
| Q2 24 | $42.4M | $101.2M |
| Q1 26 | — | $120.0M | ||
| Q4 25 | $112.9M | $129.3M | ||
| Q3 25 | $223.4M | $138.3M | ||
| Q2 25 | $109.3M | $147.2M | ||
| Q1 25 | $52.3M | $150.7M | ||
| Q4 24 | $47.1M | $162.8M | ||
| Q3 24 | $43.4M | $167.4M | ||
| Q2 24 | $49.1M | $172.6M |
| Q1 26 | — | 0.82× | ||
| Q4 25 | — | 0.69× | ||
| Q3 25 | — | 0.62× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.37× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $22.7M | $-7.1M | ||
| Q3 25 | $-4.9M | $-8.2M | ||
| Q2 25 | $-353.0K | $-3.9M | ||
| Q1 25 | $1.2M | $-13.2M | ||
| Q4 24 | $-16.7M | $-6.7M | ||
| Q3 24 | $-4.7M | $-7.2M | ||
| Q2 24 | $1.4M | $-5.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-7.1M | ||
| Q3 25 | — | $-8.3M | ||
| Q2 25 | — | $-4.0M | ||
| Q1 25 | — | $-13.5M | ||
| Q4 24 | — | $-6.8M | ||
| Q3 24 | — | $-7.7M | ||
| Q2 24 | — | $-6.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | -31.4% | ||
| Q3 25 | — | -38.4% | ||
| Q2 25 | — | -16.6% | ||
| Q1 25 | — | -60.0% | ||
| Q4 24 | — | -28.8% | ||
| Q3 24 | — | -37.6% | ||
| Q2 24 | — | -30.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
LUNG
Segment breakdown not available.
